Welcure Drugs [WELCURE] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison

Welcure Drugs

BSE
Loading...

Suven Life Sciences

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Welcure Drugs wins in 9 metrics, Suven Life Sciences wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

MetricWelcure DrugsSuven Life SciencesBetter
P/E Ratio (TTM)2.24-28.31Suven Life Sciences
Price-to-Book Ratio0.4541.36Welcure Drugs
Debt-to-Equity Ratio120.180.00Suven Life Sciences
PEG Ratio0.00-0.34Suven Life Sciences
EV/EBITDA5.57-24.12Suven Life Sciences
Profit Margin (TTM)7.96%84.44%Suven Life Sciences
Operating Margin (TTM)10.38%-2,791.92%Welcure Drugs
EBITDA Margin (TTM)10.38%N/AN/A
Return on Equity2.12%-146.15%Welcure Drugs
Return on Assets (TTM)0.81%-118.91%Welcure Drugs
Free Cash Flow (TTM)$-2.22B$-1.91BSuven Life Sciences
1-Year Return-13.65%45.95%Suven Life Sciences
Price-to-Sales Ratio (TTM)0.21632.35Welcure Drugs
Enterprise Value$1.91B$44.90BSuven Life Sciences
EV/Revenue Ratio0.59597.31Welcure Drugs
Gross Profit Margin (TTM)10.40%100.00%Suven Life Sciences
Revenue per Share (TTM)$38$0Welcure Drugs
Earnings per Share (Diluted)$2.69$-8.45Welcure Drugs
Beta (Stock Volatility)-2.070.78Welcure Drugs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Welcure Drugs vs Suven Life Sciences Stock Performance Analysis

Loading Price Chart...

Welcure Drugs
Suven Life Sciences
Welcure Drugs Stock Overview | Suven Life Sciences Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Welcure Drugs4.97%20.73%-33.73%-43.59%-19.42%-40.13%
Suven Life Sciences-1.77%0.30%-12.23%-23.53%72.40%60.12%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Welcure Drugs-13.65%-18.73%225.49%196.43%109.46%-49.31%
Suven Life Sciences45.95%208.80%320.60%-27.74%585.05%3,721.46%

News Based Sentiment: Welcure Drugs vs Suven Life Sciences

Welcure Drugs

News based Sentiment: MIXED

October was a pivotal month for Welcure Drugs, marked by a potential acquisition offer and significant financial growth, but also continued stock volatility and regulatory scrutiny. The mixed signals create a complex investment picture, making it a significant month for the company's trajectory.

View Welcure Drugs News Sentiment Analysis

Suven Life Sciences

News based Sentiment: MIXED

October was a month of conflicting signals for Suven Life Sciences. While the company benefited from a positive pharmaceutical sector rally and maintained a debt-free status, it also reported continued quarterly losses and received a negative analyst rating. This creates a complex investment narrative with both potential opportunities and significant risks.

View Suven Life Sciences News Sentiment Analysis

Performance & Financial Health Analysis: Welcure Drugs vs Suven Life Sciences

MetricWELCURESUVEN
Market Information
Market Cap i₹712.18M₹47.99B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i8,204,994184,111
90 Day Avg. Volume i6,251,926150,383
Last Close₹6.97₹201.20
52 Week Range₹5.26 - ₹15.89₹102.50 - ₹299.99
% from 52W High-56.14%-32.93%
All-Time High₹25.00 (Sep 19, 2005)₹338.50 (Apr 13, 2015)
% from All-Time High-72.12%-40.56%
Growth Metrics
Quarterly Revenue Growth-34.93%0.86%
Quarterly Earnings GrowthN/A0.86%
Financial Health
Profit Margin (TTM) i0.08%0.84%
Operating Margin (TTM) i0.10%-27.92%
Return on Equity (TTM) i0.02%-1.46%
Debt to Equity (MRQ) i120.180.00
Cash & Liquidity
Book Value per Share (MRQ)₹13.32₹5.04
Cash per Share (MRQ)₹0.01₹2.75
Operating Cash Flow (TTM) i₹-2,249,340,000₹-1,590,282,000
Levered Free Cash Flow (TTM) i₹21.70M₹-1,607,450,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A₹0.00

Valuation & Enterprise Metrics Analysis: Welcure Drugs vs Suven Life Sciences

MetricWELCURESUVEN
Price Ratios
P/E Ratio (TTM) i2.24-28.31
Forward P/E iN/A10.78
PEG Ratio i0.00-0.34
Price to Sales (TTM) i0.21632.35
Price to Book (MRQ) i0.4541.36
Market Capitalization
Market Capitalization i₹712.18M₹47.99B
Enterprise Value i₹1.91B₹44.90B
Enterprise Value Metrics
Enterprise to Revenue i0.59597.31
Enterprise to EBITDA i5.57-24.12
Risk & Other Metrics
Beta i-2.070.78
Book Value per Share (MRQ) i₹13.32₹5.04

Financial Statements Comparison: Welcure Drugs vs Suven Life Sciences

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)WELCURESUVEN
Revenue/Sales i₹3.00B₹18.67M
Cost of Goods Sold i₹2.69B₹0
Gross Profit i₹311.96M₹18.67M
Research & Development iN/A₹414.88M
Operating Income (EBIT) i₹311.36M₹-521.17M
EBITDA i₹311.41M₹-501.49M
Pre-Tax Income i₹311.36M₹-515.17M
Income Tax i₹78.37M₹0
Net Income (Profit) i₹232.99M₹-515.17M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)WELCURESUVEN
Cash & Equivalents i₹1.28M₹150.26M
Total Current Assets i₹1.82B₹754.72M
Total Current Liabilities i₹412.69M₹234.86M
Long-Term Debt i₹1.23BN/A
Total Shareholders Equity i₹1.03B₹1.10B
Retained Earnings i₹-100.79M₹-6.01B
Property, Plant & Equipment iN/A₹756.69M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)WELCURESUVEN
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricWELCURESUVEN
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i8,204,994184,111
Average Daily Volume (90 Day) i6,251,926150,383
Shares Outstanding i112.51M218.07M
Float Shares i14.84M67.61M
% Held by Insiders i0.85%0.69%
% Held by Institutions i0.00%0.02%

Dividend Analysis & Yield Comparison: Welcure Drugs vs Suven Life Sciences

MetricWELCURESUVEN
Last 12-Month Dividend iN/A₹0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A₹0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A₹0.00
Ex-Dividend DateN/AN/A